SciELO - Scientific Electronic Library Online

 
vol.134 número3Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminarIdentificación de otros agentes infecciosos en casos sospechosos de síndrome cardiopulmonar por hantavirus índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

VALDES A, María del Pilar et al. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade®). Rev. méd. Chile [online]. 2006, vol.134, n.3, pp.326-331. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872006000300009.

Background: Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful. Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-a) antibody. This mediator has a role in the pathogenesis of psoriasis. Aim: To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies. Material and Methods: An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis. They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6. Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks. Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit. Results: All the patients responded in the first 10 weeks of follow-up. The mean reduction in PASI score was 86.6%. Six patients received fourth infusion of infliximab at 37.3 weeks, on average. The most common adverse events were pruritus and headache. Conclusions: This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximab

Palabras clave : Antibodies, monoclonal; infliximab; psoriasis.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons